Oral immunoglobulin for the treatment of rotavirus diarrhea in low birth weight infants

Pammi, Mohan; Haque, Khalid N.

doi:10.1002/14651858.cd003742.pub2

Cited by 5 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Testing of these VHH constructs in a clinical setting and further evaluation of the preparations mentioned before (bovine colostrum and chicken IgY) are necessary to determine their practical utility. Furthermore, testing the value of human Ig in relevant clinical settings is necessary; for example, a recent Cochrane Database systematic review concluded that no randomized controlled trials assessing the effectiveness or safety of oral immunoglobulin preparations for the treatment of RV diarrhea in hospitalized low-birth-weight infants have been published (50).…”

Section: Therapeutic and Prophylactic Applications Of Rv Antibodiesmentioning

confidence: 99%

Rotavirus

Franco

Greenberg²

2013

Microbiol Spectr

View full text Add to dashboard Cite

Rotaviruses (RV) are ubiquitous, highly infectious, segmented double-stranded RNA genome viruses of importance in public health because of the severe acute gastroenteritis they cause in young children and many animal species. They are very well adapted to their host, with symptomatic and asymptomatic reinfections being virtually universal during the first 3 years of life. Antibodies are the major arm of the immune system responsible for protecting infants from RV reinfection. The relationship between the virus and the B cells (Bc) that produce these antibodies is complex and incompletely understood: most blood-circulating Bc that express RV-specific immunoglobulin (Ig) on their surface (RV-Ig) are naive Bc and recognize the intermediate capsid viral protein VP6 with low affinity. When compared to non-antigen-specific Bc, RV-Bc are enriched in CD27+ memory Bc (mBc) that express IgM. The Ig genes used by naive RV-Bc are different than those expressed by RV-mBc, suggesting that the latter do not primarily develop from the former. Although RV predominantly infects mature villus enterocytes, an acute systemic viremia also occurs and RV-Bc can be thought of as belonging to either the intestinal or systemic immune compartments. Serotype-specific or heterotypic RV antibodies appear to mediate protection by multiple mechanisms, including intracellular and extracellular homotypic and heterotypic neutralization. Passive administration of RV-Ig can be used either prophylactically or therapeutically. A better understanding of the Bc response generated against RV will improve our capacity to identify improved correlates of protection for RV vaccines.

show abstract

Section: Therapeutic and Prophylactic Applications Of Rv Antibodiesmentioning

confidence: 99%

Rotavirus

Franco

Greenberg²

2013

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…5 There are limited reports in the literature describing use of enteral immunoglobulins to treat rotavirus in immunocompetent infants and children as well as small case series in adult HSCT patients. [6][7][8][9] This study represents a singlecenter experience of using multiple daily doses of enteral immunoglobulins in four pediatric HSCT patients with confirmed rotavirus infections in order to decrease the severity and duration of diarrhea.…”

Section: Introductionmentioning

confidence: 99%

Treatment of rotavirus-associated diarrhea using enteral immunoglobulins for pediatric stem cell transplant patients

Williams

2014

J Oncol Pharm Pract

View full text Add to dashboard Cite

Diarrhea is a common complication associated with allogeneic and autologous stem cell transplant patients. One potential cause of viral diarrhea is rotavirus gastroenteritis. This study represents a single-center experience of using multiple daily doses of enteral immunoglobulins in four pediatric hematopoietic stem cell transplant patients with confirmed rotavirus infections. Four courses of enteral immunoglobulin administration were included for analysis. Clinical characteristics recorded included duration of diarrhea symptoms, frequency of bowel movements, and consistency of stool. Four single courses of enteral immunoglobulins in four patients were included for analysis. Patient age range was from 10 months to 14 years. Three out of four courses observed displayed an improvement in diarrhea frequency and/or stool consistency. Median time from therapy initiation to symptom improvement was three days. At a median 22-month follow-up, one patient was diagnosed with gastrointestinal graft-versus-host disease. The time to rotavirus symptom resolution was decreased, compared to historical controls, and improvement in stool frequency and consistency was observed in three of four courses. One case of gastrointestinal graft-versus-host disease was observed after nearly two years of follow-up. Enteral administration of immunoglobulins may represent a valid clinical option for hematopoietic stem cell transplant patients with rotavirus diarrhea.

show abstract

“…Special therapy of rotavirus gastroenteritis is usually not necessary, and symptomatic treatment is adequate. For severe courses, oral Ig preparations are available, but their efficacy is not definitely proven . To enable the best therapy for the patient, in case of graft‐versus‐host disease or infection (which is often difficult to distinguish between), stool specimens should be screened early and regularly.…”

Section: Discussionmentioning

confidence: 99%

Multiple viral infections after haploidentical hematopoietic stem cell transplantation in a child with acute lymphoblastic leukemia

Ernst

Sauerbrei

Krumbholz

et al. 2012

Transplant Infectious Dis

View full text Add to dashboard Cite

After allogeneic hematopoietic stem cell transplantation (HSCT), viral infections/reactivations are a frequent complication, sometimes with fatal outcome. Thus, early diagnosis is recommended by screening of whole blood or plasma preparations using highly sensitive molecular techniques that test for the most common viral pathogens, such as Epstein-Barr virus, cytomegalovirus, and adenoviruses (ADVs). Despite this approach, not every reactivation/infection can be adequately detected or excluded, even with highly sensitive polymerase chain reaction. Particularly after toxic treatment, uncommon infections or infections resistant to first-line treatment can occur, even in unusual locations. Herein, we present the case of a child with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic HSCT who suffered from 5 different viral reactivations/infections, including acyclovir-resistant herpes simplex virus type 1 esophagitis, human herpesvirus 6 encephalitis, rotavirus gastroenteritis, respiratory syncytial virus pneumonia, and ADV esophagitis, despite routinely performed blood examinations for viral pathogens remaining unrevealing at all times.

show abstract

Oral immunoglobulin for the treatment of rotavirus diarrhea in low birth weight infants

Cited by 5 publications

References 39 publications

Rotavirus

Rotavirus

Treatment of rotavirus-associated diarrhea using enteral immunoglobulins for pediatric stem cell transplant patients

Multiple viral infections after haploidentical hematopoietic stem cell transplantation in a child with acute lymphoblastic leukemia

Contact Info

Product

Resources

About